Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Mohamed Suliman

Cardiovascular Disease Ocala, FL Medical Doctor

NPI 1912496514 CMS profile 11253796

1219 S Pine Ave, Ste 204, Ocala, FL 34471

Open in the dashboard

General payments

$32,269

289 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mohamed Suliman of Ocala, FL is reported in the CMS Open Payments database as having received $32,269 across 289 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $7,910 78
2024 General $17,449 76
2023 General $3,862 80
2022 General $2,569 45
2021 General $478 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mohamed Suliman
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Mohamed Suliman were reported at $7,910. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Mohamed Suliman Cardiovascular Disease median Middle half National median
2019 $0 $450 $127–$1,392 $163
2020 $0 $242 $77–$751 $114
2021 $478 $335 $101–$1,037 $132
2022 $2,569 $395 $121–$1,211 $149
2023 $3,862 $443 $136–$1,283 $160
2024 $17,449 $450 $136–$1,323 $164
2025 $7,910 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Abbott Laboratories $10,257 10 payments
  2. Medtronic, Inc. $5,926 61 payments
  3. Terumo Medical Corporation $2,965 20 payments
  4. Boston Scientific Corporation $1,598 9 payments
  5. Edwards Lifesciences Corporation $1,587 14 payments
  6. Inari Medical, Inc. $1,463 3 payments
  7. Abiomed $1,143 11 payments
  8. Biosense Webster, Inc. $1,093 9 payments
  9. Shockwave Medical, Inc $1,003 12 payments
  10. AstraZeneca Pharmaceuticals LP $609 22 payments
  11. Other $4,626 118 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $11,757 235 payments
  2. Grant $10,563 2 payments
  3. Travel and Lodging $9,337 46 payments
  4. Education $612 6 payments
Products named General payments · program years 2021–2025
  1. GLIDESHEATH SLENDER $2,485 13 payments
  2. COREVALVE EVOLUT R $2,248 23 payments
  3. CT THROMBECTOMY SYSTEM KIT $1,463 3 payments
  4. FLOWTRIEVER CATHETER, S $1,463 3 payments
  5. Carto 3 $1,093 9 payments
  6. SAPIEN 3 Ultra RESILIA $1,078 13 payments
  7. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $690 7 payments
  8. JARDIANCE $532 10 payments
  9. LifeVest $509 21 payments
  10. XARELTO $425 15 payments
  11. Other $7,972 162 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

286

Median for Internal Medicine: 777

Drug cost

$56,988

Median for Internal Medicine: $73,373

Branded share of claims

40.6%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 28 $31,713
Xarelto Rivaroxaban Brand 11 $13,752
Praluent Pen Alirocumab Brand 20 $9,810
Chlorthalidone Generic 24 $388
Isosorbide Mononitrate Er Isosorbide Mononitrate Brand 37 $268
Nitroglycerin Generic 16 $251
Atorvastatin Calcium Generic 23 $189
Metoprolol Succinate Generic 33 $171
Clopidogrel Clopidogrel Bisulfate Brand 20 $164
Rosuvastatin Calcium Generic 28 $133

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$3,083

Medicare's payments for the services billed

Medicare patients

25

Average age 78

Services billed

39

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 72%
Ischemic heart disease 60%
Chronic kidney disease 60%
Heart failure 56%
Depression 56%
Diabetes 44%
COPD 44%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XARELTO
  • Janssen Pharmaceuticals, Inc $192
$192 11 —
WAINUA
  • AstraZeneca Pharmaceuticals LP $77
$77 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $71
$71 — —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $53
$53 — —
KENGREAL
  • CHIESI USA, INC. $20
$20 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

289 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record